New hope for ulcerative colitis sufferers: experimental drug shows promise
NCT ID NCT05377580
First seen Nov 19, 2025 · Last updated May 13, 2026 · Updated 22 times
Summary
This study tested an experimental drug called IBI112 in 150 people with moderate to severe ulcerative colitis, a chronic bowel disease causing inflammation and ulcers. The goal was to see if IBI112 could help patients achieve remission (no symptoms) after 12 weeks of treatment. Participants received either IBI112 or a placebo, and the study is now complete.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, 510080, China
Conditions
Explore the condition pages connected to this study.